Table 1.
Baseline demographic and disease specific characteristics of patients on infliximab
| N=291 | |
| Age | 35.0 (21.0) |
| Disease duration prior to IFX | 89.95 (157.2) |
| Montreal classification for Crohn’s, Age at diagnosis (years) | |
| A1 | 58 (19.9) |
| A2 | 197 (67.7) |
| A3 | 36 (12.4) |
| Montreal classification for Crohn’s, Location | |
| L1 | 41 (14.1) |
| L2 | 72 (24.7) |
| L3 | 177 (60.8) |
| +L4 | 59 (20.4) |
| +Perianal | 138 (47.4) |
| Montreal classification for Crohn’s, Behaviour | |
| B1 | 76 (26.1) |
| B2 | 45 (15.5) |
| B3 | 170 (58.4) |
| Indication for IFX | |
| Luminal CD | 184 (63.2) |
| Perianal CD | 55 (18.9) |
| Luminal+perianal CD | 52 (17.9) |
| Previous exposure to biologic, n (%) | 24 (8.2) |
| Previous intestinal surgery, n (%) | 125 (43.0) |
| Era of IFX initiation, n (%) | |
| Pre-TDM | 161 (55.3) |
| Post-TDM | 130 (44.7) |
| Patients tested for TDM, n (%) | 238 (81.8) |
| Median (range) number of TDMs per patient | 2 (0–8) |
| Interval from 1st infusion to 1st TDM (months) | 12.5 (30.2) |
| Undetectable levels episode, n (%) | 95 (40.1) |
| ATI episode, n (%) | 76 (31.9) |
| Dose intensification episode, n (%) | 62 (21.3) |
| Patients discontinued IFX due to SLR or SAE, n (%) | 109 (37.5) |
| Abdominal surgery after IFX initiation, n (%) | 44 (15.1) |
| Duration of overall follow-up (months) | 44.7 (40.3) |
All values represent median (IQR) unless otherwise indicated. Time and duration is expressed in months.
ATI, antibodies to infliximab; CD, Crohn’s disease; IFX, infliximab; SAE, serious adverse event; SLR, secondary loss of response; TDM, therapeutic drug monitoring.